logo
Maison
au sujet de nous
Profil d'entreprise
visite d'usine
contrôle de qualité
produits

Dérivés de la cellulose

Dérivés de l'amidon

Couche de comprimés

sel inorganique

Sphères de sucre pharmaceutiques

Série de résines

Excipients pharmaceutiques

silice

Stéarate de magnésium

CMC Carboxyméthyl cellulose

Glucolate d'amidon de sodium

HPMC de l'hypromellose

Cellulose microcristalline MCC

Amidon traité à l'acide

Agents de revêtement composés

Épaississant composé
vidéo
Événements
nouvelles
les affaires
contactez-nous
Causez Maintenant
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
maison
au sujet de nous
produits

Dérivés de la cellulose

Dérivés de l'amidon

Couche de comprimés

sel inorganique

Sphères de sucre pharmaceutiques

Série de résines

Excipients pharmaceutiques

silice

Stéarate de magnésium

CMC Carboxyméthyl cellulose

Glucolate d'amidon de sodium

HPMC de l'hypromellose

Cellulose microcristalline MCC

Amidon traité à l'acide

Agents de revêtement composés

Épaississant composé
vidéo
Événements
nouvelles
les affaires
contactez-nous
Cité
le drapeau le drapeau

DÉTAILS DE NOUVELLES
Maison > Nouvelles >

Actualités de l'entreprise Independent Innovation in Co‑processed Excipients — Sunhere Excipients Empowers Global Formulation R&D

Événements

Nouvelles

Les affaires
Contactez-nous
Ms. Haileeping
haileeping@sunhere-excipients.com
86-0554-2796186
Contact maintenant

Independent Innovation in Co‑processed Excipients — Sunhere Excipients Empowers Global Formulation R&D

2026-08-20

Co‑processed excipients are key functional materials for oral solid dosage forms. Unlike conventionally physically blended pre‑mixed excipients, they undergo special co‑processing technologies to reconstruct the microscopic powder structure, which markedly improves powder flowability, compressibility and disintegration performance. They greatly simplify the direct‑compression formulation process and shorten formulation R&D cycles, making them a vital option for the development of modified‑release preparations and innovative drugs. For a long time, the domestic high‑end co‑processed excipient market has been heavily reliant on imports, with supply‑chain risks, high costs and registration‑document constraints restricting the development of pharmaceutical formulation enterprises.


As a leading domestic pharmaceutical excipient enterprise, Sunhere Excipients has devoted itself to tackling technical challenges in co‑processed excipients. It has established a complete system covering R&D, pilot‑scale testing and GMP‑compliant production, broken down overseas technical barriers, and realized domestic substitution for multiple core co‑processed excipients. The company provides stable, compliant and high‑performance domestic solutions for pharmaceutical enterprises at home and abroad.

1.Deep‑dive into Co‑processing Technology to Consolidate Core Strength in Independent R&D

Leveraging years‑long technical accumulation in cellulose‑based excipients, Sunhere Excipients has assembled a professional R&D team for co‑processed excipients. It has built full‑chain R&D capabilities covering lab‑scale formula screening, process development, stability investigation, pilot‑scale scale‑up and commercial production. The company masters core co‑processing technologies rather than simple material blending. Targeted optimization of powder properties is achieved by modulating the microscopic morphology of materials.

At present, the company has launched a range of mature products including co‑processed excipients of microcrystalline cellulose‑colloidal silicon dioxide, microcrystalline cellulose‑sodium carboxymethylcellulose, lactose‑powdered cellulose, mannitol‑microcrystalline‑croscarmellose calcium, and calcium stearate‑sodium lauryl sulfate. Among them, the co‑processed excipient of microcrystalline cellulose and colloidal silicon dioxide has obtained the first dual registration filing in China and the United States among domestic manufacturers. Its performance is comparable to equivalent imported international products, enabling direct import substitution. It supports formulation registration applications both domestically and overseas, helping pharmaceutical enterprises get rid of constraints from the supply chain of imported excipients.

The products comply with pharmacopoeial standards of ChP, USP, EP and other national pharmacopoeias, and can meet domestic and overseas registration requirements such as associated review and DMF filing. They have been verified and applied in multiple marketed pharmaceutical formulations.

2.Scale up Continuous Investment to Lay Out the Future Development of Co‑processed Excipients

In the coming years, Sunhere Excipients will continue to increase R&D investment in the co‑processed excipient track, expand its product portfolio of co‑processed excipients, and develop more novel co‑processed varieties suitable for modified‑release, high‑drug‑loading and poorly‑compressible APIs.


It will continuously optimize the processes of existing products, improve batch‑to‑batch consistency and scale up large‑scale production capacity; enhance domestic and overseas registration qualifications to consolidate the foundation for global supply; strengthen technical service capabilities and establish in‑depth collaboration with formulation developers to address practical formulation pain points faced by pharmaceutical enterprises. Beyond standardized co‑processed excipient products, we also offer custom development services for pharmaceutical companies at home and abroad. Tailored proprietary co‑processed excipients can be developed according to customers’ API characteristics, formulation processes, performance indicators and registration requirements. We provide one‑stop collaborative development support covering formula development, process exploration, lab‑scale and pilot trials, as well as GMP‑compliant large‑scale production, to accommodate diverse R&D demands for generic drugs, modified new drugs and innovative drugs.



le drapeau
DÉTAILS DE NOUVELLES
Maison > Nouvelles >

Actualités de l'entreprise-Independent Innovation in Co‑processed Excipients — Sunhere Excipients Empowers Global Formulation R&D

Événements

Nouvelles

Les affaires

Independent Innovation in Co‑processed Excipients — Sunhere Excipients Empowers Global Formulation R&D

2026-08-20

Co‑processed excipients are key functional materials for oral solid dosage forms. Unlike conventionally physically blended pre‑mixed excipients, they undergo special co‑processing technologies to reconstruct the microscopic powder structure, which markedly improves powder flowability, compressibility and disintegration performance. They greatly simplify the direct‑compression formulation process and shorten formulation R&D cycles, making them a vital option for the development of modified‑release preparations and innovative drugs. For a long time, the domestic high‑end co‑processed excipient market has been heavily reliant on imports, with supply‑chain risks, high costs and registration‑document constraints restricting the development of pharmaceutical formulation enterprises.


As a leading domestic pharmaceutical excipient enterprise, Sunhere Excipients has devoted itself to tackling technical challenges in co‑processed excipients. It has established a complete system covering R&D, pilot‑scale testing and GMP‑compliant production, broken down overseas technical barriers, and realized domestic substitution for multiple core co‑processed excipients. The company provides stable, compliant and high‑performance domestic solutions for pharmaceutical enterprises at home and abroad.

1.Deep‑dive into Co‑processing Technology to Consolidate Core Strength in Independent R&D

Leveraging years‑long technical accumulation in cellulose‑based excipients, Sunhere Excipients has assembled a professional R&D team for co‑processed excipients. It has built full‑chain R&D capabilities covering lab‑scale formula screening, process development, stability investigation, pilot‑scale scale‑up and commercial production. The company masters core co‑processing technologies rather than simple material blending. Targeted optimization of powder properties is achieved by modulating the microscopic morphology of materials.

At present, the company has launched a range of mature products including co‑processed excipients of microcrystalline cellulose‑colloidal silicon dioxide, microcrystalline cellulose‑sodium carboxymethylcellulose, lactose‑powdered cellulose, mannitol‑microcrystalline‑croscarmellose calcium, and calcium stearate‑sodium lauryl sulfate. Among them, the co‑processed excipient of microcrystalline cellulose and colloidal silicon dioxide has obtained the first dual registration filing in China and the United States among domestic manufacturers. Its performance is comparable to equivalent imported international products, enabling direct import substitution. It supports formulation registration applications both domestically and overseas, helping pharmaceutical enterprises get rid of constraints from the supply chain of imported excipients.

The products comply with pharmacopoeial standards of ChP, USP, EP and other national pharmacopoeias, and can meet domestic and overseas registration requirements such as associated review and DMF filing. They have been verified and applied in multiple marketed pharmaceutical formulations.

2.Scale up Continuous Investment to Lay Out the Future Development of Co‑processed Excipients

In the coming years, Sunhere Excipients will continue to increase R&D investment in the co‑processed excipient track, expand its product portfolio of co‑processed excipients, and develop more novel co‑processed varieties suitable for modified‑release, high‑drug‑loading and poorly‑compressible APIs.


It will continuously optimize the processes of existing products, improve batch‑to‑batch consistency and scale up large‑scale production capacity; enhance domestic and overseas registration qualifications to consolidate the foundation for global supply; strengthen technical service capabilities and establish in‑depth collaboration with formulation developers to address practical formulation pain points faced by pharmaceutical enterprises. Beyond standardized co‑processed excipient products, we also offer custom development services for pharmaceutical companies at home and abroad. Tailored proprietary co‑processed excipients can be developed according to customers’ API characteristics, formulation processes, performance indicators and registration requirements. We provide one‑stop collaborative development support covering formula development, process exploration, lab‑scale and pilot trials, as well as GMP‑compliant large‑scale production, to accommodate diverse R&D demands for generic drugs, modified new drugs and innovative drugs.



Lien rapide
Maison Au sujet de nous Produits Vidéo Nouvelles Les affaires Contactez-nous
Contactez rapidement

Adresse

ZONE DE DÉVELOPEMENT ÉCONOMIQUE ET TECHNOLOGIQUE,HUAINAN,ANHUI 232007,Chine La région de développement économique et technologique,HUAINAN,ANHUI 232007,Chine

Téléphone

86-0554-2796186

Notre newsletter
Abonnez-vous à notre newsletter pour des réductions et plus encore.
Politique en matière de protection de la vie privée |  Plan du site  | Bonne qualité de la Chine Dérivés de la cellulose Fournisseur. © de Copyright 2024-2026 Anhui Sunhere Pharmaceutical Excipients Co., Ltd. . Tous droits réservés.